Tripelennamine Hydrochloride

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Feb 19, 1948	PbzNDA 5914 · New molecular entity	Novartis	2	Discontinued
Jul 5, 1956	Pbz-SrNDA 10533 · New formulation or manufacturer	Novartis	13	Discontinued
Sep 27, 1972	Tripelennamine HydrochlorideANDA 80744	Barr	0	Discontinued
Jan 18, 1973	Tripelennamine HydrochlorideANDA 80713	Watson Labs	12	Discontinued
Sep 6, 1973	PbzANDA 83149	Novartis	10	Discontinued
May 10, 1974	Tripelennamine HydrochlorideANDA 83557	Lannett	1	Discontinued
Aug 11, 1976	Tripelennamine HydrochlorideANDA 85188	Watson Labs	0	Discontinued
—	Tripelennamine HydrochlorideANDA 80785	Impax Labs	0	Discontinued
—	Tripelennamine HydrochlorideANDA 80790	Watson Labs	0	Discontinued
—	Tripelennamine HydrochlorideANDA 83037	Anabolic	0	Discontinued
—	Tripelennamine HydrochlorideANDA 83625	Parke Davis	0	Discontinued
—	Tripelennamine HydrochlorideANDA 83626	Parke Davis	0	Discontinued
—	Tripelennamine HydrochlorideANDA 83989	Heather	0	Discontinued
—	Tripelennamine HydrochlorideANDA 85412	Nylos	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA